Tsu Vivien D, Mai Tran T P, Nguyen Yen H, Luu Huong T T
PATH, Seattle, WA 98107, USA.
J Obstet Gynaecol Res. 2006 Oct;32(5):489-96. doi: 10.1111/j.1447-0756.2006.00436.x.
The study was undertaken to meet the need of the Ministry of Health to have local evidence on the effectiveness of active management of third-stage labor (AMTSL) in reducing the incidence of postpartum hemorrhage (PPH) > or = 500 mL and the need for PPH treatment.
Using a quasi-experimental design, AMTSL was introduced for all births attended by government midwives (at home, community, and district levels) in one district while standard practice without AMTSL was continued in three neighboring districts (with a 1:2 ratio of participants). Oxytocin (10 IU) was administered either by standard disposable syringe and needle or by a prefilled, single-use injection device. Postpartum blood loss was estimated using standard containers; other outcome measures included the duration of third stage, the need for additional treatments, and final maternal condition. A total of 3607 women participated (1236 in the intervention district and 2371 in the comparison districts). Multivariate logistic regression was used to control for age, parity, place of delivery, and first-stage oxytocin augmentation.
AMTSL was associated with reduced risks for prolonged third stage beyond 30 min (odds ratio [OR] = 0.20, 95%; confidence interval [CI]: 0.11, 0.35), supplemental oxytocin (OR = 0.68, 95% CI: 0.49, 0.94), and bimanual compression (OR = 0.63, 95%; CI: 0.41, 0.98). When cases with first-stage oxytocin augmentation were excluded, AMTSL was associated with a 34% reduction in PPH incidence (OR = 0.66, 95%; CI: 0.45, 0.98).
This study supports the value of AMTSL in reducing the incidence of PPH, shortening the third stage of labor, and reducing the need for additional treatments.
开展本研究是为了满足卫生部的需求,即获取关于第三产程积极管理(AMTSL)在降低产后出血(PPH)≥500 mL发生率及PPH治疗需求方面的本地证据。
采用准实验设计,在一个地区对政府助产士(在家中、社区和区级)接生的所有产妇引入AMTSL,而在三个相邻地区继续采用无AMTSL的标准做法(参与者比例为1:2)。催产素(10 IU)通过标准一次性注射器和针头或预填充一次性注射装置给药。使用标准容器估计产后失血量;其他结局指标包括第三产程持续时间、额外治疗需求及产妇最终状况。共有3607名妇女参与(干预地区1236名,对照地区2371名)。采用多因素逻辑回归控制年龄、产次、分娩地点及第一产程催产素加强使用情况。
AMTSL与第三产程延长超过30分钟的风险降低相关(优势比[OR]=0.20,95%;置信区间[CI]:0.11,0.35)、补充催产素(OR=0.68,95%CI:0.49,0.94)及双手压迫(OR=0.63,95%;CI:0.41,0.98)。排除第一产程使用催产素加强的病例后,AMTSL与PPH发生率降低34%相关(OR=0.66,95%;CI:0.45,0.98)。
本研究支持AMTSL在降低PPH发生率、缩短第三产程及减少额外治疗需求方面的价值。